Sinovant Sciences and Nabriva Therapeutics (NBRV) Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients treated with moxifloxacinLefamulin was generally safe and well-tolerated in Chinese adultsGreater Chinese rights to lefamulin will be held by Sumitomo Pharmaceuticals (Suzhou) Co., Ltd., a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese... More